Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas

Anirban Maitra, Dana Wanzer, Arthur G. Weinberg, Raheela Ashfaq

Research output: Contribution to journalArticle

Abstract

BACKGROUND. Recent reports have described overexpression of p185 c-erbB2, the product of the HER-2/neu oncogene, in more than 40% of archival osteosarcomas that were examined by immunohistochemistry (IHC). However, IHC can be influenced by the method of fixation, extent of antigen retrieval, specificity and sensitivity of the antibody clone, and the use of an arbitrary semiquantitative scoring system. In contrast, fluorescence in situ hybridization (FISH) assays that assess HER-2/neu gene copy numbers in individual cells are more consistent, more reproducible, and less subjective than IHC. METHODS. The authors examined pretreatment nondecalcified archival tissue from 21 high-grade pediatric osteosarcomas for amplification of the HER-2/neu oncogene using an Food and Drug Administration (FDA)-approved FISH assay (Path-Vysion, Vysis Inc., Downers Grove, IL). Additionally, IHC for p185c-erbB2 was performed in all cases using the Dako polyclonal antibody clone A0485 (Dako Co., Carpinteria, CA). RESULTS. None of the 21 osteosarcomas had evidence of HER-2/neu gene amplification by FISH, whereas p185c-erbB2 IHC was negative in all cases. CONCLUSIONS. HER-2/neu gene amplification appeared to be an uncommon event in pediatric osteosarcomas. The reason(s) for discordance between previous IHC data and the current FISH and IHC results was unknown, but might reflect intrinsic variations in antibody clones, or might suggest that, in some cases, the occurrence of protein overexpression is independent of gene amplification.

Original languageEnglish (US)
Pages (from-to)677-683
Number of pages7
JournalCancer
Volume92
Issue number3
DOIs
StatePublished - Aug 1 2001
Externally publishedYes

Fingerprint

erbB-2 Genes
Osteosarcoma
Oncogenes
Immunohistochemistry
Pediatrics
Fluorescence In Situ Hybridization
Gene Amplification
Clone Cells
Gene Dosage
Antibody Specificity
Antibodies
United States Food and Drug Administration
Antigens
Sensitivity and Specificity

Keywords

  • ERBB-2
  • FISH
  • HER-2/neu
  • Osteosarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. / Maitra, Anirban; Wanzer, Dana; Weinberg, Arthur G.; Ashfaq, Raheela.

In: Cancer, Vol. 92, No. 3, 01.08.2001, p. 677-683.

Research output: Contribution to journalArticle

Maitra, Anirban ; Wanzer, Dana ; Weinberg, Arthur G. ; Ashfaq, Raheela. / Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas. In: Cancer. 2001 ; Vol. 92, No. 3. pp. 677-683.
@article{5a459a7564824b28bb78a87ec431701b,
title = "Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas",
abstract = "BACKGROUND. Recent reports have described overexpression of p185 c-erbB2, the product of the HER-2/neu oncogene, in more than 40{\%} of archival osteosarcomas that were examined by immunohistochemistry (IHC). However, IHC can be influenced by the method of fixation, extent of antigen retrieval, specificity and sensitivity of the antibody clone, and the use of an arbitrary semiquantitative scoring system. In contrast, fluorescence in situ hybridization (FISH) assays that assess HER-2/neu gene copy numbers in individual cells are more consistent, more reproducible, and less subjective than IHC. METHODS. The authors examined pretreatment nondecalcified archival tissue from 21 high-grade pediatric osteosarcomas for amplification of the HER-2/neu oncogene using an Food and Drug Administration (FDA)-approved FISH assay (Path-Vysion, Vysis Inc., Downers Grove, IL). Additionally, IHC for p185c-erbB2 was performed in all cases using the Dako polyclonal antibody clone A0485 (Dako Co., Carpinteria, CA). RESULTS. None of the 21 osteosarcomas had evidence of HER-2/neu gene amplification by FISH, whereas p185c-erbB2 IHC was negative in all cases. CONCLUSIONS. HER-2/neu gene amplification appeared to be an uncommon event in pediatric osteosarcomas. The reason(s) for discordance between previous IHC data and the current FISH and IHC results was unknown, but might reflect intrinsic variations in antibody clones, or might suggest that, in some cases, the occurrence of protein overexpression is independent of gene amplification.",
keywords = "ERBB-2, FISH, HER-2/neu, Osteosarcoma",
author = "Anirban Maitra and Dana Wanzer and Weinberg, {Arthur G.} and Raheela Ashfaq",
year = "2001",
month = "8",
day = "1",
doi = "10.1002/1097-0142(20010801)92:3<677::AID-CNCR1370>3.0.CO;2-V",
language = "English (US)",
volume = "92",
pages = "677--683",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "3",

}

TY - JOUR

T1 - Amplification of the HER-2/neu oncogene is uncommon in pediatric osteosarcomas

AU - Maitra, Anirban

AU - Wanzer, Dana

AU - Weinberg, Arthur G.

AU - Ashfaq, Raheela

PY - 2001/8/1

Y1 - 2001/8/1

N2 - BACKGROUND. Recent reports have described overexpression of p185 c-erbB2, the product of the HER-2/neu oncogene, in more than 40% of archival osteosarcomas that were examined by immunohistochemistry (IHC). However, IHC can be influenced by the method of fixation, extent of antigen retrieval, specificity and sensitivity of the antibody clone, and the use of an arbitrary semiquantitative scoring system. In contrast, fluorescence in situ hybridization (FISH) assays that assess HER-2/neu gene copy numbers in individual cells are more consistent, more reproducible, and less subjective than IHC. METHODS. The authors examined pretreatment nondecalcified archival tissue from 21 high-grade pediatric osteosarcomas for amplification of the HER-2/neu oncogene using an Food and Drug Administration (FDA)-approved FISH assay (Path-Vysion, Vysis Inc., Downers Grove, IL). Additionally, IHC for p185c-erbB2 was performed in all cases using the Dako polyclonal antibody clone A0485 (Dako Co., Carpinteria, CA). RESULTS. None of the 21 osteosarcomas had evidence of HER-2/neu gene amplification by FISH, whereas p185c-erbB2 IHC was negative in all cases. CONCLUSIONS. HER-2/neu gene amplification appeared to be an uncommon event in pediatric osteosarcomas. The reason(s) for discordance between previous IHC data and the current FISH and IHC results was unknown, but might reflect intrinsic variations in antibody clones, or might suggest that, in some cases, the occurrence of protein overexpression is independent of gene amplification.

AB - BACKGROUND. Recent reports have described overexpression of p185 c-erbB2, the product of the HER-2/neu oncogene, in more than 40% of archival osteosarcomas that were examined by immunohistochemistry (IHC). However, IHC can be influenced by the method of fixation, extent of antigen retrieval, specificity and sensitivity of the antibody clone, and the use of an arbitrary semiquantitative scoring system. In contrast, fluorescence in situ hybridization (FISH) assays that assess HER-2/neu gene copy numbers in individual cells are more consistent, more reproducible, and less subjective than IHC. METHODS. The authors examined pretreatment nondecalcified archival tissue from 21 high-grade pediatric osteosarcomas for amplification of the HER-2/neu oncogene using an Food and Drug Administration (FDA)-approved FISH assay (Path-Vysion, Vysis Inc., Downers Grove, IL). Additionally, IHC for p185c-erbB2 was performed in all cases using the Dako polyclonal antibody clone A0485 (Dako Co., Carpinteria, CA). RESULTS. None of the 21 osteosarcomas had evidence of HER-2/neu gene amplification by FISH, whereas p185c-erbB2 IHC was negative in all cases. CONCLUSIONS. HER-2/neu gene amplification appeared to be an uncommon event in pediatric osteosarcomas. The reason(s) for discordance between previous IHC data and the current FISH and IHC results was unknown, but might reflect intrinsic variations in antibody clones, or might suggest that, in some cases, the occurrence of protein overexpression is independent of gene amplification.

KW - ERBB-2

KW - FISH

KW - HER-2/neu

KW - Osteosarcoma

UR - http://www.scopus.com/inward/record.url?scp=0035423782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035423782&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(20010801)92:3<677::AID-CNCR1370>3.0.CO;2-V

DO - 10.1002/1097-0142(20010801)92:3<677::AID-CNCR1370>3.0.CO;2-V

M3 - Article

C2 - 11505415

AN - SCOPUS:0035423782

VL - 92

SP - 677

EP - 683

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 3

ER -